FIELD: medicine.
SUBSTANCE: for treatment of the said conditions, anti-NKG2A-antibody or antigen binding fragment thereof are applied.
EFFECT: use of inventions allows to stop bone erosion or cartilage destruction, mediated by osteoclasts and fibroblast-like synoviocytes, by lysis of the latter using specific NK-cells of the synovial membrane expressing NKG2A, induced by anti-NKG2A-antibodies.
15 cl, 25 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO NKG2A AND THEIR APPLICATIONS | 2007 |
|
RU2499001C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| NEUROENDOCRINE FACTORS FOR TREATING DEGENERATIVE DISORDERS | 2008 |
|
RU2496790C2 |
| RA ANTIGEN PEPTIDES | 2004 |
|
RU2359974C2 |
